Vivex Biomedical, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2017 | $6 M | No. 3 | $2 to $10 million | equity | SEC | |
| Dec 2015 | $7 M | No. 2 | $2 to $10 million | equity | SEC | |
| Jul 2013 | $7 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Vivex Biomedical, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (May 2017).
SEC Form D (revenue range) · May 2017
Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2013; revenue between $25 million and $100 million in 2016; revenue between $25 million and $100 million in 2017.
SEC Form D (revenue range) · May 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2017
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Vivex Biomedical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 51 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dr. H Thomas Temple | Chief Medical Officer | May 2017 |
| Holly S. Mason | Executive officer | May 2017 |
| Stuart J Komenski | Chief Financial Officer | May 2017 |
| Timothy Thomas Ganey, Ph.D. | Chief Scientific Officer | May 2017 |
| Tracy S. Anderson | President and Chief Executive Officer | May 2017 |
| Dr. H. Thomas Temple | Chief Medical Officer | Jan 2016 |
| Ricardo J. Nunez | General Counsel and Corporate Secretary | Jan 2016 |
| Thomas J. Gibson | Chief Financial Officer | Jan 2016 |
| Timothy J. Ganey, Ph.D. | Chief Scientific Officer | Jan 2016 |
| Holly Mason | Executive officer | Sep 2013 |
| John Marsh | Executive officer | Sep 2013 |
| Michael Rozmajzl | Executive officer | Sep 2013 |
| Tracy Anderson | Executive officer | Sep 2013 |
| Barry Thomas Salzman | Executive Chairman of Board of Directors | May 2017 |
| J. Miguel Fernandez de Castro | Director | May 2017 |
| James K. Price | Director | May 2017 |
| John A. McCallum | Director | May 2017 |
| Richard E. Perlman | Director | May 2017 |
| Timothy S. Taylor | Chairman of Board of Directors | May 2017 |
| Tracy S. Anderson | President and Chief Executive Officer | May 2017 |
| U. Bertram Ellis, Jr. | Director | May 2017 |
| Barry J. Salzman | Executive Chairman of Board of Directors | Jan 2016 |
| Jeffrey A. Smith | Director | Jan 2016 |
| Timothy J. Taylor | Chairman of Board of Directors | Jan 2016 |
| David R. Greenberg | Director | Sep 2013 |
| H. Thomas Temple | Director | Sep 2013 |
| John Bertram McCallum | Director | Sep 2013 |
| Jouko R. Rissanen | Director | Sep 2013 |
| Saadiq Thomas El-Amin, III | Director | Sep 2013 |
| Thomas A. Greene | Director | Sep 2013 |
| Timothy Lusby | Director | Sep 2013 |
| Timothy Taylor | Director | Sep 2013 |
| Tracy Anderson | Director | Sep 2013 |